Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Antibodies in Drug Discovery

Roger Beerli's Biography

Roger Beerli, CSO, NBE Therapeutics

Roger Beerli serves as Chief Scientific Officer (CSO) at NBE Therapeutics since April 2013. Roger Beerli has over 10 years of experience in discovery, engineering and preclinical development of therapeutic antibodies. Previously he has led R&D activities related to therapeutic antibody development at Cytos, Switzerland, and later at Intercell, Austria. Roger is a renowned expert in mammalian cell based antibody expression and display for the discovery of fully human therapeutic antibodies. He was the main architect and inventor of Cytos' eMAB® mammalian cell antibody development platform, which, under Roger's leadership, was successfully used for the development of fully human therapeutic antibody candidates against numerous targets, including Nicotine and Influenza A, both at Cytos, and also later at Intercell, after the platform had been acquired by Intercell. Roger Beerli studied molecular biology at the University of Zurich, Switzerland, and obtained his PhD for work at the Novartis-associated Friedrich Miescher Institute in Basel, Switzerland, for research on ErbB receptor tyrosine kinases. Afterwards he performed postdoctoral research at The Scripps Research Institute in La Jolla, California, USA, in the lab of Prof. Dr. Carlos F. Barbas III. Here he specialized in phage display for protein and antibody engineering and was among the first to demonstrate artificial regulation of endogenous genes using engineered transcription factors. ?Roger Beerli has published widely in the areas of protein discovery, protein engineering and antibody development, and he is co-inventor on numerous patents and patent applications.

Roger Beerli Image

Sortase-mediated Antibody Conjugation (SMAC™): Generation of Homogeneous, Site-specifically Conjugated Antibody Drug Conjugates

Wednesday, 10 February 2016 at 14:30

Add to Calendar ▼2016-02-10 14:30:002016-02-10 15:30:00Europe/LondonSortase-mediated Antibody Conjugation (SMAC™): Generation of Homogeneous, Site-specifically Conjugated Antibody Drug ConjugatesAntibodies in Drug Discovery in Cambridge, UKCambridge,

This presentation describes a novel enzymatic conjugation platform that provides a robust and efficient means to attach toxic payloads to antibodies and yields homogenous drug products with pre-defined drug-to-antibody ratios.

Add to Calendar ▼2016-02-09 00:00:002016-02-10 00:00:00Europe/LondonAntibodies in Drug DiscoveryAntibodies in Drug Discovery in Cambridge, UKCambridge,